Dr. Daruka Mahadevan named director of the Institute for Drug Development
Daruka Mahadevan, MD, PhD, chief of the Division of Hematology-Oncology, was appointed to two new expanded leadership roles at the Mays Cancer Center.
In addition to being chief of hematology-oncology, Dr. Mahadevan will assume the roles of director of the Institute for Drug Development and associate director for clinical research. Dr. Mahadevan is a world-renowned expert in early phase drug development. He is deeply passionate about clinical research, its conduct and the central role that investigational trials play in the care of cancer patients at a National Cancer Institute-designated Cancer Center.
Dr. Mahadevan joined the Mays Cancer Center in August 2019 from the University of Arizona, where he was the director of the Early Phase Therapeutics Program and co-director of Experimental Therapeutic Development at the University of Arizona Cancer Center, an NCI-designated Comprehensive Cancer Center. During his time in Arizona, Dr. Mahadevan was a mentee of Daniel D. Von Hoff, MD, FACP, FASCO, FAACR, the founding director of the May’s Cancer Center’s Institute for Drug Development.
Dr. Mahadevan will work closely with the leadership team at the Mays Cancer Center, the Clinical Trials Office and all clinical investigators to advance the goals of the IDD. These goals include increasing investigator-initiated trials across disciplines, increasing patient enrollment in treatment trials and maintaining and growing our minority patient participation into cancer clinical trials.